VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
企業コードVNRX
会社名VolitionRX Ltd
上場日Feb 06, 2015
最高経営責任者「CEO」Dr. Jasmine Kway
従業員数85
証券種類Ordinary Share
決算期末Feb 06
本社所在地1489 West Warm Springs Road
都市HENDERSON
証券取引所NYSE American Consolidated
国United States of America
郵便番号89014
電話番号17024251561
ウェブサイトhttps://volition.com/
企業コードVNRX
上場日Feb 06, 2015
最高経営責任者「CEO」Dr. Jasmine Kway
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし